Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

Bottom line: Antimicrobial peptides can selectively kill cancer cells via membrane disruption, but no AMP has yet advanced beyond early-phase oncology trials — optimizing stability and delivery remains the critical translational hurdle.

Antimicrobial peptides (AMPs) are short, cationic, amphipathic peptides that constitute an evolutionarily ancient arm of innate immunity. While primarily studied for their antibacterial and antifungal properties, a growing body of evidence demonstrates their selective cytotoxicity against tumor cells — a property driven by fundamental differences in cancer cell membrane composition.

Key Mechanisms of Anticancer Activity

The review published in Frontiers in Medicine identifies several mechanisms by which AMPs target malignant cells:¹

• Membrane disruption: Cancer cells expose phosphatidylserine on their outer membrane leaflet, creating an electrostatic gradient that attracts cationic AMPs. Healthy cells maintain this phospholipid on the inner leaflet, conferring selectivity.
• Apoptosis induction: Several AMPs activate intrinsic apoptotic pathways through mitochondrial membrane permeabilization, distinct from their membrane-lytic activity.
• Anti-angiogenic effects: Certain AMPs (e.g., angiostatin-derived peptides) inhibit tumor vascularization by targeting endothelial cell proliferation.
• Immune modulation: Some AMPs recruit and activate dendritic cells and natural killer cells within the tumor microenvironment.

Selectivity Data

Preclinical studies consistently report therapeutic indices (IC₅₀ against tumor cells / IC₅₀ against normal cells) ranging from 5:1 to >100:1 for optimized AMPs, though these ratios diminish in more complex in vivo models.

Translational Challenges

Despite promising preclinical profiles, the review highlights critical barriers:

• Proteolytic instability: Serum proteases rapidly degrade linear AMPs, limiting systemic half-life to minutes.
• Delivery: Most AMP candidates require intratumoral injection or nanoparticle encapsulation for efficacy.
• Manufacturing cost: Solid-phase peptide synthesis at clinical scale remains expensive compared to small-molecule drugs.
• Limited clinical evidence: Most oncology data come from Phase I safety studies with small cohorts.

Clinical Implication

For oncologists, AMPs are not ready for clinical use but warrant monitoring as a mechanistically distinct class — particularly for drug-resistant tumors where conventional chemotherapy fails. The membrane-targeting mechanism bypasses most known resistance pathways (efflux pumps, target mutations). Research groups developing peptide drug conjugates and nanoparticle delivery systems may unlock the clinical potential of this class within the next 3–5 years.

---

¹ Advances in antimicrobial peptides: promising cancer therapeutics. Frontiers in Medicine. 2026;doi:10.3389/fmed.2026.1783547.